145.75 USD
-0.25 (-0.17%)
145.45 USD
-0.3 (-0.21%)
Overall TMDX gets a fundamental rating of 6 out of 10. We evaluated TMDX against 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of TMDX get a neutral evaluation. Nothing too spectacular is happening here. TMDX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, TMDX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year TMDX was profitable.
In the past year TMDX had a positive cash flow from operations.
In the past 5 years TMDX reported 4 times negative net income.
In the past 5 years TMDX reported 4 times negative operating cash flow.
1.2 Ratios
TMDX has a better Return On Assets (9.71%) than 92.55% of its industry peers.
Looking at the Return On Equity, with a value of 25.88%, TMDX belongs to the top of the industry, outperforming 96.28% of the companies in the same industry.
TMDX has a better Return On Invested Capital (8.72%) than 87.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| ROIC | 8.72% |
ROA(3y)-4.09%
ROA(5y)-12.79%
ROE(3y)-7.43%
ROE(5y)-23.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of TMDX (16.22%) is better than 92.55% of its industry peers.
With an excellent Operating Margin value of 16.89%, TMDX belongs to the best of the industry, outperforming 87.23% of the companies in the same industry.
TMDX has a Gross Margin of 60.28%. This is comparable to the rest of the industry: TMDX outperforms 59.57% of its industry peers.
In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.89% | ||
| PM (TTM) | 16.22% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
TMDX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for TMDX has been increased compared to 1 year ago.
The number of shares outstanding for TMDX has been increased compared to 5 years ago.
The debt/assets ratio for TMDX has been reduced compared to a year ago.
2.2 Solvency
TMDX has an Altman-Z score of 6.10. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
TMDX's Altman-Z score of 6.10 is fine compared to the rest of the industry. TMDX outperforms 78.72% of its industry peers.
The Debt to FCF ratio of TMDX is 4.27, which is a neutral value as it means it would take TMDX, 4.27 years of fcf income to pay off all of its debts.
TMDX has a Debt to FCF ratio of 4.27. This is in the better half of the industry: TMDX outperforms 79.79% of its industry peers.
TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
TMDX has a worse Debt to Equity ratio (1.43) than 79.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.27 | ||
| Altman-Z | 6.1 |
ROIC/WACC1.09
WACC8.01%
2.3 Liquidity
TMDX has a Current Ratio of 7.66. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.66, TMDX belongs to the top of the industry, outperforming 89.36% of the companies in the same industry.
TMDX has a Quick Ratio of 7.10. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.10, TMDX belongs to the top of the industry, outperforming 89.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.66 | ||
| Quick Ratio | 7.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 162.77% over the past year.
Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 41.20%.
The Revenue has been growing by 79.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
The Earnings Per Share is expected to grow by 44.52% on average over the next years. This is a very strong growth
TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.23% yearly.
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 59.01, TMDX can be considered very expensive at the moment.
TMDX's Price/Earnings ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 69.15% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.15, TMDX is valued quite expensively.
TMDX is valuated quite expensively with a Price/Forward Earnings ratio of 49.95.
TMDX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 69.68% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of TMDX to the average of the S&P500 Index (36.12), we can say TMDX is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.01 | ||
| Fwd PE | 49.95 |
4.2 Price Multiples
TMDX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 69.15% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, TMDX is valued a bit cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.5 | ||
| EV/EBITDA | 41.32 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.74% in the coming years.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y69.97%
EPS Next 3Y53.74%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
145.75
-0.25 (-0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.43%
Inst Owner Change1.45%
Ins Owners2.96%
Ins Owner Change-0.12%
Market Cap4.98B
Revenue(TTM)566.35M
Net Income(TTM)91.86M
Analysts83.16
Price Target146.29 (0.37%)
Short Float %22.8%
Short Ratio7.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)-2.1%
PT rev (3m)-5.02%
EPS NQ rev (1m)1.89%
EPS NQ rev (3m)3.41%
EPS NY rev (1m)9.81%
EPS NY rev (3m)10%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)0.44%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-0.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.01 | ||
| Fwd PE | 49.95 | ||
| P/S | 8.79 | ||
| P/FCF | 41.5 | ||
| P/OCF | 27.98 | ||
| P/B | 14.03 | ||
| P/tB | 14.6 | ||
| EV/EBITDA | 41.32 |
EPS(TTM)2.47
EY1.69%
EPS(NY)2.92
Fwd EY2%
FCF(TTM)3.51
FCFY2.41%
OCF(TTM)5.21
OCFY3.57%
SpS16.57
BVpS10.39
TBVpS9.98
PEG (NY)0.36
PEG (5Y)N/A
Graham Number24.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| ROCE | 11.04% | ||
| ROIC | 8.72% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 19.58% | ||
| OM | 16.89% | ||
| PM (TTM) | 16.22% | ||
| GM | 60.28% | ||
| FCFM | 21.19% |
ROA(3y)-4.09%
ROA(5y)-12.79%
ROE(3y)-7.43%
ROE(5y)-23.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.27 | ||
| Debt/EBITDA | 4.17 | ||
| Cap/Depr | 223.08% | ||
| Cap/Sales | 10.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.33% | ||
| Profit Quality | 130.63% | ||
| Current Ratio | 7.66 | ||
| Quick Ratio | 7.1 | ||
| Altman-Z | 6.1 |
F-Score7
WACC8.01%
ROIC/WACC1.09
Cap/Depr(3y)950.14%
Cap/Depr(5y)614.59%
Cap/Sales(3y)35.03%
Cap/Sales(5y)23.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
EBIT growth 1Y204.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.7%
EBIT Next 3Y89.1%
EBIT Next 5Y68.49%
FCF growth 1Y186.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y801.62%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
What is the valuation status for TMDX stock?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for TMDX stock?
The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 59.01 and the Price/Book (PB) ratio is 14.03.
What is the financial health of TRANSMEDICS GROUP INC (TMDX) stock?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 6 / 10.